We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.75B
AUM Growth
-$879M
Cap. Flow
-$770M
Cap. Flow %
-44.05%
Top 10 Hldgs %
36.57%
Holding
112
New
6
Increased
25
Reduced
47
Closed
16

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$12.8M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$12M
3
EVH icon
Evolent Health
EVH
+$6.42M
4
MRUS
Merus
MRUS
+$3.85M
5
ACHC icon
Acadia Healthcare
ACHC
+$3.72M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$63M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$55.9M
3
FRPT icon
Freshpet
FRPT
+$48.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$41.7M
5
UNH icon
UnitedHealth
UNH
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.7%
2 Consumer Staples 0%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
51
Agios Pharmaceuticals
AGIO
$1.95B
$10M 0.57%
342,180
-128,906
-27% -$4.28M
PHVS icon
52
Pharvaris
PHVS
$2.43B
$9.79M 0.56%
623,402
-151,729
-20% -$2.56M
CMPX icon
53
Compass Therapeutics
CMPX
$400M
$9.43M 0.54%
4,962,955
-816,620
-14% -$2.17M
ELVN icon
54
Enliven Therapeutics
ELVN
$4.35B
$9.17M 0.52%
465,871
+37,300
+9% +$803K
SLNO
55
DELISTED
Soleno Therapeutics
SLNO
$8.87M 0.51%
124,095
– –
ARDX icon
56
Ardelyx
ARDX
$997M
$7.88M 0.45%
1,604,975
+141,346
+10% +$759K
ACRS icon
57
Aclaris Therapeutics
ACRS
$868M
$7.72M 0.44%
5,046,309
-1,158,000
-19% -$2.47M
ZBIO
58
Zenas BioPharma
ZBIO
$2.02B
$6.94M 0.4%
878,667
– –
ETNB
59
DELISTED
89bio
ETNB
$6.14M 0.35%
844,441
+291,700
+53% +$2.55M
PRTA icon
60
Prothena Corp
PRTA
$468M
$6.1M 0.35%
492,601
-152,000
-24% -$2.15M
JANX icon
61
Janux Therapeutics
JANX
$1B
$5.52M 0.32%
204,466
– –
DYN icon
62
Dyne Therapeutics
DYN
$4.95B
$5.49M 0.31%
524,499
+49,971
+11% +$715K
MLYS icon
63
Mineralys Therapeutics
MLYS
$2.41B
$5.09M 0.29%
+320,813
New +$3.69M
CGEM icon
64
Cullinan Oncology
CGEM
$1.18B
$4.88M 0.28%
644,633
-97,481
-13% -$935K
NVRO
65
DELISTED
NEVRO CORP.
NVRO
$4.67M 0.27%
800,494
-847,606
-51% -$4.47M
BCAX
66
Bicara Therapeutics
BCAX
$1.82B
$4.38M 0.25%
336,070
-109,905
-25% -$1.46M
NVAX icon
67
Novavax
NVAX
$1.3B
$4.17M 0.24%
650,000
– –
KMTS
68
Kestra Medical Technologies
KMTS
$1.66B
$3.61M 0.21%
+145,000
New +$3.33M
GOSS icon
69
Gossamer Bio
GOSS
$86.1M
$3.59M 0.21%
3,266,960
– –
LUNG icon
70
Pulmonx
LUNG
$97.9M
$3.39M 0.19%
503,700
-268,451
-35% -$1.9M
INZY
71
DELISTED
Inozyme Pharma
INZY
$3.14M 0.18%
3,445,299
-416,684
-11% -$578K
BEAM icon
72
Beam Therapeutics
BEAM
$2.82B
$2.93M 0.17%
150,020
-102,203
-41% -$2.68M
ATEC icon
73
Alphatec Holdings
ATEC
$1.47B
$2.71M 0.16%
267,500
+67,500
+34% +$725K
SGMT icon
74
Sagimet Biosciences
SGMT
$591M
$2.57M 0.15%
787,808
– –
FOCL
75
EDAP TMS S.A.
FOCL
$228M
$2.49M 0.14%
1,270,000
-321,800
-20% -$767K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Rock Springs Capital Management held 112 positions worth $1.75B, down 33% from $2.63B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management withdrew a net $770M in Q1 2025, closing 16 positions and reducing 47 holdings. Its most notable exit was Freshpet, an estimated $48.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Danaher worth $12.1M.

  • Rock Springs Capital Management's largest Q1 2025 buy was Danaher: 58,800 shares worth $12.1M.
  • Rock Springs Capital Management added most to Tarsus Pharmaceuticals in Q1 2025, an estimated $12M increase.
  • Rock Springs Capital Management's biggest Q1 2025 reduction was Intuitive Surgical, cutting an estimated $63M.
  • Rock Springs Capital Management fully exited Freshpet in Q1 2025, selling an estimated $48.5M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $1.75B portfolio in Q1 2025.
  • Rock Springs Capital Management opened 6 new positions and closed 16 in Q1 2025.
  • Rock Springs Capital Management's portfolio value fell 33% quarter-over-quarter to $1.75B.

Based on Rock Springs Capital Management's 13F filing for Q1 2025, filed 15 May 2025.